Minocycline-induced Conjunctival Hyperpigmentation : Ophthalmic Plastic & Reconstructive Surgery

Secondary Logo

Journal Logo

OPRS Images

Minocycline-induced Conjunctival Hyperpigmentation

Lin, Lisa Y. M.D., M.B.E.*; Stagner, Anna M. M.D.; Freitag, Suzanne K. M.D.*

Author Information
Ophthalmic Plastic and Reconstructive Surgery: November 17, 2022 - Volume - Issue - 10.1097/IOP.0000000000002278
doi: 10.1097/IOP.0000000000002278
  • Free
  • PAP

A 73-year-old woman presented with a 1-year history of pigmented conjunctival lesions in both eyes. She had been taking minocycline for decades for recurrent facial cysts. On examination, she had a larger pigmented cystic lesion of her right inferior fornix conjunctiva, and several smaller hyperpigmented lesions in her right inferior, left superior, and left inferior palpebral conjunctivae (Panel A; external photograph). She underwent an excisional biopsy of the large cyst. Pathology showed exogenous brownish-gray pigment granules (circle) deposited in macrophages surrounding vessels in the substantia propia (Panel B; hematoxylin & eosin-stained image at 40× magnification). The pigment granules were stained black (arrow) with Fontana-Masson stain (Panel C; image at 40×). There was no evidence of an atypical melanocytic proliferation. A diagnosis of minocycline-induced hyperpigmentation was made. Minocycline, a tetracycline antibiotic, can be used to treat dermatologic conditions. Extended use can lead to hyperpigmentation of the skin, nails, teeth, oral mucosa, sclera, and conjunctiva. There is a wide range of reported doses and duration of therapy associated with mucosal or cutaneous hyperpigmentation varying by type and site, occurring as early as days to weeks, with a median onset of 1–2 years. Cosmetic concerns should prompt discontinuation, although hyperpigmentation is likely permanent. These lesions were not visually significant nor bothersome, and therefore no additional treatment was recommended.

F1
© 2022 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc.